贝达药业：四款药纳入2025年国家医保药品目录

Core Viewpoint - The announcement by Beida Pharmaceutical regarding the inclusion of its products in the National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List for 2025 is a significant development for the company and its market positioning [1] Group 1 - Beida Pharmaceutical has announced that its products, including Alectinib Hydrochloride Tablets, Ensartinib Capsules, Bafetinib Mesylate Capsules, and Vorinostat Tablets, have been included in the National Drug List for 2025 [1]